Gene Universal Inc.

Maravai LifeSciences | April 27, 2020

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infecti...

INDUSTRIAL IMPACT

Biocytogen | July 21, 2022

Biocytogen Pharmaceuticals Co., Ltd. entered a strategic collaboration with LiberoThera Co., Ltd to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excellent anti-tumo...

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...